Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief ...

Monte Rosa Therapeutics, Inc. ( (GLUE)) has released its Q3 earnings. Here is a breakdown of the information Monte Rosa Therapeutics, Inc. presented to its investors. Monte Rosa Therapeutics, Inc. is ...

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 35.56% and 103.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the ...

Monte Rosa Therapeutics signed a development and commercialization deal with Novartis that could pay the biotech up to $2.1 ...

Executed global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed molecular glue degraders including MRT-6160 for immune-related conditions; $150M ...

BOSTON (AP) — BOSTON (AP) — Monte Rosa Therapeutics Inc. (GLUE) on Thursday reported a loss of $23.9 million in its third quarter. The Boston-based company said it had a loss of 29 cents per share.

TD Cowen analyst Marc Frahm has maintained their bullish stance on GLUE stock, giving a Buy rating on October 28. Marc Frahm has given his Buy ...

The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 100.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ...

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) was able to establish a partnership deal with Novartis AG (NVS) to develop a molecular glue degrader [MGD] drug known as MRT-6160 for the treatment of ...

Monte Rosa Therapeutics Inc. saw its stock more than double on Monday after the Boston biotech announced a deal with Novartis. The deal centers around Monte Rosa’s molecular glue degrader-based ...

Monte Rosa to receive up-front payment of $150 million and is eligible to receive milestone payments, U.S. profit and loss share, and tiered royalties on ex-U.S. net sales BOSTON, Oct. 28 ...

Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies, and tiered royalties on ex-U.S. net sales.